← brief for 2026-09-16 · Slowing decline

Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3–5 chronic kidney disease: a retrospective real-world study

Key takeaways

This study looked back at the records of people with stage 3 to 5 kidney disease who took dupilumab for moderate to severe eczema. Dupilumab is an injected drug for eczema. The study checked how well the drug worked and whether it was safe in people with weaker kidneys. It is a look back at medical records, so it can show a pattern, not proof. No abstract was available, so we could not check how many people were studied or what side effects were seen.

Who did this work

Jiali Wei (Shaoxing Second Hospital) · Yiqi Huang (Shaoxing Second Hospital)

Source

Paper · OpenAlex, CKD works · 2026-09-14
https://doi.org/10.3389/fmed.2026.1906235